{"id":4006,"date":"2025-03-31T18:11:55","date_gmt":"2025-03-31T18:11:55","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/fluvastatin-txt\/"},"modified":"2025-03-31T18:11:55","modified_gmt":"2025-03-31T18:11:55","slug":"fluvastatin-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/fluvastatin-txt\/","title":{"rendered":"Fluvastatin.txt"},"content":{"rendered":"

Fluvastatin <\/h1>\n

CLINICAL USE <\/H3>
\nHMG CoA reductase inhibitor:Primary hypercholesterolaemia Slowing progression of atherosclerosis Secondary prevention of coronary events after percutaneous coronary intervention

DOSE IN NORMAL RENAL FUNCTION <\/H3>20\u201380 mg daily in the eveningXL: 80 mg daily

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :433.4 (as sodium salt)<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :>98<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 6<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.35<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :1.4\u20133.2\/\u2013

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Removal unlikely. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Removal unlikely. Dose as in normal renal function
  • HDF\/high flux &nbsp :Removal unlikely. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Removal unlikely. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Antibacterials: rifampicin increases metabolism; increased risk of myopathy with daptomycin\n
  • Anticoagulants: anticoagulant effect enhanced\n
  • Ciclosporin: concomitant treatment with ciclosporin may lead to risk of muscle toxicityColchicine: isolated cases of myopathy have been reportedLipid-lowering drugs: increased risk of myopathy with gemfibrozil, fibrates and nicotinic acid \u2013 avoid concomitant use with gemfibrozil

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>The Committee on Safety of Medicines has advised that rhabdomyolysis associated with lipid-lowering drugs, such as the fibrates and statins, appears to be rare (approx. 1 case in every 100 000 treatment years), but may be increased in those with renal impairment and possibly in those with hypothyroidismManufacturer\u2019s literature indicates fluvastatin is contraindicated in patients with severe renal impairment (creatinine greater than or equal to 160 \u00b5mol\/L).
    \n","protected":false},"excerpt":{"rendered":"

    Fluvastatin CLINICAL USE HMG CoA reductase inhibitor:Primary hypercholesterolaemia Slowing progression<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4006","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4006","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4006"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4006\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4006"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4006"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4006"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}